Your commercial lens on the pharmaceutical industry

At Evaluate we collect, calibrate and connect the pharmaceutical world’s data

Evaluate is not a package I can do without. It’s an absolute timesaver

Anthony M, Senior Director, Competitive Intelligence & Prospection

NOVARTIS

Evaluate is such an important resource for us; it makes all of our lives easier

Vishwas S, Vice President

BANK OF AMERICA

Evaluate Pharma helps pharmaceutical companies reduce the cost, time and risk of making strategic decisions

Evaluate Pharma gives you a comprehensive understanding of the global pharmaceutical industry’s past, present and future performance. With over two decades of commercial data and consensus forecasts to 2026, you get a seamless 27-year view of the commercial issues driving the sector.

From an overview of the broader market to a detailed product or company analysis, Evaluate Pharma’s integrated platform takes you from exploration to full understanding as quickly and accurately as possible.

With solutions for asset screening, market analysis, competitive intelligence and portfolio strategy, Evaluate Pharma broadens your insight and reduces the cost, time and risk associated with making informed, strategic decisions.

Size new markets

Carry out market

landscaping

Benchmark deals

Build forecasts and financial

models

Screen and value

assets

Identify and track

competitors

Stay abreast of industry

trends

Evaluate Pharma gives you the time and confidence to turn knowledge into insight, and insight into action

Comprehensive commercial dataEvaluate Pharma is your most comprehensive source of commercial information on the past, present and future of the industry. It covers every commercially relevant marketed product, and all disclosed clinical development products, supported by the largest back catalogue of consensus drug forecasts.

Rapidly unlock market insightsDynamic summary pages and powerful, interactive dashboards enable you to quickly explore and assess pharmaceutical markets and their underlying dynamics, transforming complex data into actionable insights.

Trust through transparencyEvaluate Pharma data is trusted by the industry, including all of the top 25 global pharma companies, for high value decisions and external analyst presentations. Our team of experts put the data through a rigorous quality assurance process, backed up by our transparent proprietary methodologies, so you always have confidence in the results.

Consensus Forecasts to 2026Our deep industry knowledge and analytical expertise allow us to create the highest quality consensus forecasts so you can benchmark strategic decisions with confidence.

• Industry-leading broker coverage

• Historical and forecast sales broken down by indication

• Understand the dynamics of each market

DealsWe offer comprehensive coverage of M&A, licensing, venture financing and IPO deals in the pharmaceutical and biotech space.

• Track and benchmark deals by product classification (phase of development, therapy area, technology and phase of compounds)

• Review deal values, upfront payments, royalties and co-promotions

• Evaluate any company’s M&A record and follow product progress after acquisition

Archive Sales ForecastsWe have the largest back catalogue of consensus drug forecasts, including a monthly archive of Evaluate’s Consensus Forecasts so you can see changes versus the current forecast.

• Contains 485,000 forecasts covering 11,000+ drugs since January 2003

• Provides unique insights into equity analysts’ changing sales expectations through a drug’s life cycle

• Monitor a drug’s progression with real-world information and understand changes in forecast commercial potential

Company FinancialsOur extensive company-level financial information – both historical and forecast – identifies the leading companies in the industry in terms of their revenues and profits, covering:

• Profit and loss (reported and normalized)

• Balance sheet and cash flow information

• Product and therapy area sales

• Portfolio performance

R&D Pipeline and Portfolio AnalysisWe cover R&D pipeline information at each stage of the process, from research and development to filed and approved.

• Build customized views of the development landscape

• Cut data by phase, indication, therapy area, mechanism of action, company and technology

• See regulatory approvals history across USA, EU, Japan and Brazil, plus key patent expiration dates

Event AnalyzerOur Event Analyzer reveals the news events that affect pharmaceutical and biotech company share prices and valuations.

• Curated by event type, including clinical trial results, regulatory decisions, competitor announcements, financial results, patent litigation and broker sentiment

• Share price and market capitalization change calculated for each event

• Daily and weekly round-ups of stock price winners and losers

Add more insights to your Evaluate Pharma subscription

Streamline your research process with rapid market insights

Market LandscapeUncover insights about the market and drill-down into each indication for a deeper understanding of global sales, market share, mechanism of action and more.

Market DynamicsUnderstand the underlying dynamics influencing the market value and quickly identify the market leaders, disruptors and significant growth drivers and brakes.

Portfolio AnalyzerCompare company portfolios by indication or technology to determine strengths and weaknesses. Or combine them to identify possible M&A opportunities through hybrid portfolios.

• ConsensusForecasts to 2026

• Historical Salesfrom 1986

• Archive SalesForecasts

• Sales by Indication

• Sales byTherapeutic Area

• Orphan Drugs

• Biosimilars

• Pharma Class

• Sales, Volume andPricing USA, Europe,Japan and Brazil

• Company Financials

• Portfolio Analysis

• Patent Risk

• Pipeline FreshnessIndex

• Venture Financingand IPO

• M&A Analysis

• Company Profiles

• Daily Vantage News

• Drug Profiles

• TrackingDrugs@FDA

• Approvals EMEA

• Uptake Curves

• Expedited Approvals

• Licensing Deals

• Event Analyzer

• R&D Pipeline

• Peer Group Analyzer

• Merge Company

• Customized reportingand easy export

• Easy integrationof reports intoworkflows via plugins

• Priority ReviewVouchers

Our interactive suite of tailored dashboards deliver an intuitive and visual solution for answering key market questions

Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalized, expert support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential.

offers a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2026, company financials, pipelines and deals.

tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2026, company financials and more.

improves your strategic decision-making with customized solutions and deep insights that draw on our industry expertise and trusted commercial intelligence.

provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate’s commercial intelligence.

Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom

T +44 (0)20 7377 0800

Evaluate Americas EvaluatePharma USA Inc. 60 State Street, Suite 1910 Boston, MA 02109 USA

T +1 617 573 9450

Evaluate Asia Pacific Evaluate Japan KK Holland Hills Mori Tower 2F 5-11-2 Toranomon, Minato-ku Tokyo 105-0001, Japan

T +81 (0)80 1 164 4754

www.evaluate.com | @EvaluatePharma @EvaluateVantage

FEB 2021